These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 11732230)

  • 41. Features of the Renin-angiotensin system in ascites and pleural effusion during severe ovarian hyperstimulation syndrome.
    Delbaere A; Bergmann PJ; Englert Y
    J Assist Reprod Genet; 1997 May; 14(5):241-4. PubMed ID: 9147235
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessment of cells in the ascitic fluid of women with ovarian hyperstimulation syndrome: the clinical implications for subsequent ovarian malignancy.
    Hatzipetros I; Gocze PM; Cziraky K; Kovacs K; Kalman E; Farkas B
    Reprod Biol Endocrinol; 2013 Sep; 11():91. PubMed ID: 24028152
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome.
    Abramov Y; Barak V; Nisman B; Schenker JG
    Fertil Steril; 1997 Feb; 67(2):261-5. PubMed ID: 9022600
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of resistant ascites by continuous ultrafiltration--reinfusion of ascitic fluid.
    Villeneuve JP; Thuot C; Marleau D; Joly JG; Huet PM; Viallet A
    Can Med Assoc J; 1977 Dec; 117(11):1296-8. PubMed ID: 72594
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Update on ovarian hyperstimulation syndrome: part 2--clinical signs and treatment.
    Binder H; Dittrich R; Einhaust F; Krieg J; Müller A; Strauss R; Beckmann MW; Cupisti S
    Int J Fertil Womens Med; 2007; 52(2-3):69-81. PubMed ID: 18320864
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome.
    McClure N; Healy DL; Rogers PA; Sullivan J; Beaton L; Haning RV; Connolly DT; Robertson DM
    Lancet; 1994 Jul; 344(8917):235-6. PubMed ID: 7913160
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of intraperitoneal cytokines and nitrites in women with severe ovarian hyperstimulation syndrome.
    Revel A; Barak V; Lavy Y; Anteby E; Abramov Y; Schenker JJ; Amit A; Finci-Yeheskel Z; Mayer M; Simon A; Laufer N; Hurwitz A
    Fertil Steril; 1996 Jul; 66(1):66-71. PubMed ID: 8752613
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Role of intercellular adhesion molecule-1 and E-selectin in the pathogenesis of ovarian hyperstimulation syndrome].
    Kovachev E; Kozovski I; Markova V; Gemer O; Cherneva S
    Akush Ginekol (Sofiia); 2005; 44(4):26-31. PubMed ID: 16028375
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Association between renin activity, angiotensin II and ovarian hyperstimulation syndrome].
    Fan Y; Chen G
    Zhonghua Fu Chan Ke Za Zhi; 2001 Nov; 36(11):647-50. PubMed ID: 11930686
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Ovarian hyperstimulation syndrome--prevention and treatment].
    Grønlund LA; Bogstad JW
    Ugeskr Laeger; 1996 Dec; 158(50):7205-9. PubMed ID: 9012033
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of ascites. Paracentesis as a guide.
    Habeeb KS; Herrera JL
    Postgrad Med; 1997 Jan; 101(1):191-2, 195-200. PubMed ID: 9008697
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Non-invasive ventilation for the treatment of acute respiratory failure following ovarian hyperstimulation syndrome: report of two cases and a brief review of the literature.
    Barlascini C; Piroddi MG; Perazzo A; Senarega R; Santo M; Nicolini A
    Pneumologia; 2015; 64(2):30-4. PubMed ID: 26506672
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Videos in clinical medicine. Paracentesis.
    Thomsen TW; Shaffer RW; White B; Setnik GS
    N Engl J Med; 2006 Nov; 355(19):e21. PubMed ID: 17093242
    [No Abstract]   [Full Text] [Related]  

  • 54. [Concentration and reinfusion of ascitic fluid in liver cirrhosis].
    Mian G; Triolo L; Magris D; de Savorgnani MN; G'Agnolo B
    Minerva Med; 1979 Sep; 70(42):2869-72. PubMed ID: 492554
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The ascites in the ovarian hyperstimulation syndrome does not originate from the ovary.
    Yarali H; Fleige-Zahradka BG; Yuen BH; McComb PF
    Fertil Steril; 1993 Mar; 59(3):657-61. PubMed ID: 8458471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Day care management of severe ovarian hyperstimulation syndrome avoids hospitalization and morbidity.
    Shrivastav P; Nadkarni P; Craft I
    Hum Reprod; 1994 May; 9(5):812-4. PubMed ID: 7929727
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasma immunoglobulins in patients with severe ovarian hyperstimulation syndrome.
    Abramov Y; Naparstek Y; Elchalal U; Lewin A; Schechter E; Schenker JG
    Fertil Steril; 1999 Jan; 71(1):102-5. PubMed ID: 9935124
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characteristics of Patients and Their Ascites Who Underwent Repeated Cell-Free and Concentrated Ascites Reinfusion Therapy.
    Maeda S; Yabuuchi J; Nobuta H; Makiishi T; Hirose K
    Ther Apher Dial; 2015 Aug; 19(4):342-8. PubMed ID: 26386222
    [TBL] [Abstract][Full Text] [Related]  

  • 59. What to do when leak happens.
    Küttner-Magalhães R; Moreira T; Barrias S; Pedroto I
    Liver Int; 2014 Sep; 34(8):1287. PubMed ID: 24279579
    [No Abstract]   [Full Text] [Related]  

  • 60. Single center experience of cell-free and concentrated ascites reinfusion therapy in malignancy related ascites.
    Ito T; Hanafusa N; Fukui M; Yamamoto H; Watanabe Y; Noiri E; Iwase S; Miyagawa K; Fujita T; Nangaku M
    Ther Apher Dial; 2014 Feb; 18(1):87-92. PubMed ID: 24499089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.